Technion Patents Heparanase-Neutralizing A54 mAb
Summary
The USPTO granted patent US12606637B2 to Technion Research & Development Foundation Limited on April 21, 2026. The patent covers heparanase-neutralizing monoclonal antibody A54 (IgG-1 mAb), its epitope HBD-II, pharmaceutical compositions, and uses for treating cancer, inflammation, viral infections, diabetes, and related complications. The patent also discloses combinatorial cancer therapies combining the A54 mAb with chemotherapy or radiation.
What changed
Technion Research & Development Foundation Limited received granted patent protection for monoclonal antibody A54, which binds and neutralizes heparanase, an enzyme implicated in cancer metastasis, inflammatory responses, and viral infections. The patent (4 claims, CPC: C07K 16/40) covers the antibody itself, its epitope (HBD-II), pharmaceutical compositions, and therapeutic uses including combinatorial cancer therapies.\n\nCompetitors developing heparanase-targeting therapeutics or diagnostic products should conduct freedom-to-operate analyses to assess potential patent infringement exposure from this newly granted patent.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Heparanase-neutralizing A54 monoclonal antibody
Grant US12606637B2 Kind: B2 Apr 21, 2026
Assignee
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Inventors
Israel Vlodavsky, Uri Barash
Abstract
The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.
CPC Classifications
C07K 16/40 C07K 2317/565 C07K 2317/76 A61P 35/04 A61P 35/00 A61K 31/69 A61K 31/7068 A61K 39/3955 A61K 2039/505
Filing Date
2021-07-06
Application No.
18014530
Claims
4
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.